Cartesian Therapeutics (RNAC) Interest Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Interest Expenses data on file, last reported at $1.2 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 268.77% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $370000.0, a 99.72% decrease from a year earlier, with the FY2025 full-year figure at $296.9 million, up 19.79% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.2 million, up from -$2.1 million in the prior quarter.
• Over the last five years, Interest Expenses for RNAC reached as high as $130.5 million in Q4 2023 and fell as low as -$2.1 million in Q4 2025.
• Historically, Interest Expenses has averaged $13.0 million across 5 years, with a median of $1.2 million in 2026.
• Across the five-year window, Interest Expenses surged 9119.86% in 2023 and sank 310.39% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $1.4 million in 2022, then jumped by 9119.86% to $130.5 million in 2023, then sank by 99.23% to $1.0 million in 2024, then sank by 310.39% to -$2.1 million in 2025, then surged by 154.96% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $1.2 million in Q1 2026, -$2.1 million in Q4 2025, and $5.1 million in Q3 2025.